Isoxsuprine hydrochloride is used as a beta-adrenergic receptor agonist with vasodilatory activity; it inhibits circular chemorepellent-induced defect (CCID) formation in a dose-dependent manner (5 to 60 μM); suppresses 12(S)-HETE synthesis; inhibits the induction of all three motility markers (MLC2, MYPT, and paxillin); and reduces total infarct volume in vivo (from 279±25 mm³ in vehicle-treated animals to 137±18 mm³ in treated animals).